FindMyKOL

Nishaki Mehta, MD

Basic profile

Associate Professor of Medicine, William Beaumont Oakland University School of Medicine · Beaumont Health

ORCID↗NPI↗
✓ Itemized record
Region🇺🇸 Royal Oak, MI · Midwest · United StatesSpecialtyClinical Cardiac ElectrophysiologyFocusCardiac Arrhythmias and Treatments+4
Active KOLFindMyKOL type: EliteLatest publicationSee ScholarshipOnline presenceverified 2026Payments2021 onwardNIH fundingNot yet indexedWhy? →

Nishaki Mehta is Associate Professor of Medicine, William Beaumont Oakland University School of Medicine at Beaumont Health. OpenAlex indexes 177 publications with 818 citations (h-index 16); ClinicalTrials.gov lists 2 registered studies matched to this name.

Overview

Updated 29 Oct 2026

Nishaki Mehta, M.D., is Associate Professor of Medicine, William Beaumont Oakland University School of Medicine at Corewell Health William Beaumont University Hospital. The public record shows 177 publications with 826 citations (h-index 16), centered on Cardiac Arrhythmias and Treatments, Atrial Fibrillation Management and Outcomes, Cardiac pacing and defibrillation studies. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 12 companies.

  • Most recent indexed publication: 2026 · Journal of interventional cardiac electrophysiology
  • Top research focus: Cardiac Arrhythmias and Treatments
  • 4 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 12 companies

Generated from the cited public record · current as of 29 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Atrial Fibrillation4 trialsArrhythmias, Cardiac1 trial

Research focus

OpenAlex concept fingerprint
Cardiac Arrhythmias and TreatmentsAtrial Fibrillation Management and OutcomesCardiac pacing and defibrillation studiesCardiac electrophysiology and arrhythmiasCardiac Valve Diseases and Treatments

Drugs & molecules

across trials, industry payments and publications
SotalolClinical trials—Industry payments4Publications—Eliquisgeneric · ApixabanClinical trials—Industry payments1Publications—Leqviogeneric · InclisiranClinical trials—Industry payments1Publications—Multaqgeneric · DronedaroneClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Boston Scientific CorporationClinical trials1Industry payments48Medtronic, Inc.Clinical trials—Industry payments98Abbott LaboratoriesClinical trials—Industry payments49Biosense Webster, Inc.Clinical trials—Industry payments10ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)Clinical trials—Industry payments10AltaThera Pharmaceuticals LLCClinical trials—Industry payments4Biotronik Inc.Clinical trials—Industry payments2AbiomedClinical trials—Industry payments1Ablacon, Inc.Clinical trials1Industry payments—Cardiva Medical, Inc.Clinical trials—Industry payments1Corewell Health EastClinical trials1Industry payments—Johns Hopkins UniversityClinical trials1Industry payments—Novartis Pharmaceuticals CorporationClinical trials—Industry payments1Pfizer Inc.Clinical trials—Industry payments1Sanofi-Aventis U.S. LLCClinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
177publications

Distinct works indexed by OpenAlex, matched via ORCID.

818citations

Total citations across indexed works.

16h-index

Hirsch index (OpenAlex). i10-index 23.

Clinical & industry

trials, payments and federal funding
2clinical trials

Investigator role on registered studies.

View trials ↓
12companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 29 Oct 2026

Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 29 Oct 2026

12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    65.7%
    Beta blocker18.7%
    Metoprolol Succinate56%Carvedilol23%Metoprolol Tartrate21%
    Part D<11 patients
    Antiarrhythmic16.1%
    Amiodarone Hcl54%Flecainide Acetate28%Multaq18%
    Part D<11 patients

    + 7 more classes in this area

  • Blood & clotting

    31.2%
    Factor Xa inhibitor31.2%
    Eliquis80%Xarelto20%
    Part D≥52 patients
  • Metabolism & gastrointestinal

    3.2%
    SGLT2 inhibitor3.2%
    Jardiance100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Updated 29 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 29 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Sula Mazimba37David E. Haines35Kenneth C. Bilchick33Younghoon Kwon24Khadijah K Breathett18James Michael Mangrum15Abhishek J. Deshmukh14Kuldeep Bharat Shah14Nolan Shoukri13Sourbha S. Dani12Ilana B. Kutinsky12Yong Hao Yeo11Christopher V. DeSimone10Luai Madanat10William G. Stevenson10Simon R. Dixon9Usha B. Tedrow9Pamela Kay Mason8Mohamed Rafa Labedi8Nicholas Ashur8Evan Harmon8Rohit Malhotra8Patrick L. Stafford7Harsh Patel7Sahitya Allam6Jorge E. Romero6Aakash Rajendra Sheth6Richard J. Bloomingdale6Roy M. John6Samarthkumar J. Thakkar6Joshua France6Jane Chanda Kabwe5Gurukripa N. Kowlgi5Saurabh Kumar5Brittney Z. Heard5Bruce A. Koplan5Edward Rojas-Pena5Amr E. Abbas5Olivia Ondigi5Sunil Kapur5

Online presence

Updated 29 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/nishaki-mehta-md

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 29 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”